Drugs / BIROPEPIMUT-S
BIROPEPIMUT-S
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02873819 | Mar 2017 → May 2021 | oral cavity squamous cell carcinoma | Gliknik Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01245673 | May 2011 → Dec 2015 | plasma cell myeloma | University of Pennsylvania | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2012-12-20 | Gliknik Inc. | Results Gliknik Announces Interim Clinical Data From Use of Its Immunomodulator Drug Candidate in Multiple Myeloma Patients gliknik.com ↗
Based on the interim analysis, researchers saw a 180-day rate of complete or partial response of 96 percent. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-12-20 | Gliknik Inc. | Gliknik Announces Interim Clinical Data From Use of Its Immunomodulator Drug Candidate in Multiple Myeloma Patients gliknik.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIROPEPIMUT-S | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990004 ↗ |
| Known as | GL-0817 | “we evaluated the safety and activity of ex vivo expanded autologous T cells primed in vivo using a MAGE-A3 multipeptide vaccine (compound GL-0817) combined with Poly-ICLC...” PMID 24520093 ↗ Feb 2014 |
| Known as | MAGE-A3 multipeptide vaccine | “we evaluated the safety and activity of ex vivo expanded autologous T cells primed in vivo using a MAGE-A3 multipeptide vaccine (compound GL-0817) combined with Poly-ICLC...” PMID 24520093 ↗ Feb 2014 |
| Known as | MAGE-A3 Trojan Peptide Vaccine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990004 ↗ |
| Modality | Vaccine | “Subjects in active treatment will be vaccinated with GL-0817” NCT02873819 ↗ |
| Route | Intravenous | “GL-0817, IV at the dose 1.5 mg will be administered” NCT02873819 ↗ |
| Target | MAGEA3 | “Melanoma-associated antigen 3 vaccine antigen” CHEMBL3990004 ↗ |